Recent Developments in Iron Chelation Therapy

Abstract

Since 1962, desferrioxamine (deferoxamine, DFO) has been utilized for the treatment of secondary hemosiderosis. For about 30 years, DFO therapy has been performed as nightly continuous subcutaneous infusion. About 20 years ago, the first oral iron chelator (deferiprone, DFP) was presented. Concerns about potential side effects were responsible for the late acceptance and license of this drug which is limited to the use as second-line therapy for patients with thalassemia major. During recent years, chelation therapy and its evaluation started to progress rapidly. Clinical research and drug development as well as the introduction of new methods for the assessment of iron overload contributed to these advances. By using cardiac T2^* MRI it was possible to examine the specific effect of a chelator on myocardial siderosis. Clinical studies using this method indicated superiority of DFP compared to DFO with respect to the treatment of myocardial siderosis. Several retrospective and first prospective clinical trials seem to confirm this observation.

In parallel, treatment strategies based on the combination of DFO and DFP have been developed. Using both drugs simultaneously or sequentially, additive and synergistic effects contribute to the fast elimination of iron from different organs at risk for siderotic damage.

Deferasirox (DSX) is a recently developed oral chelator which shows good efficacy and tolerability in patients with transfusional hemosiderosis due to various underlying disorders. Long-term studies will define the future importance of DSX for iron chelation treatment.

For the first time, there is a choice between three commercially available chelating agents for patients with transfusional iron overload. This will allow a highly effective, individually tailored treatment hopefully leading to a fundamental improvement of patients' life expectancy and quality.

Zusammenfassung

Seit 1962 wird Desferrioxamin (Deferoxamin, DFO) zur Behandlung der transfusionsbedingten Hämosiderose eingesetzt, seit fast dreißig Jahren in Form einer nächtlichen subkutanen Infusion. Große Hoffnungen wurden später in den vor 20 Jahren in Studien entwickelten, ersten oralen Chelatbildner Deferipron (DFP) gesetzt. Vor allem Bedenken hinsichtlich des Nebenwirkungspotentials führten zur späten Akzeptanz des Chelators und zur Begrenzung des Einsatzes von DFP auf die Sekundärtherapie bei Patienten mit Thalassaemia major.

In den letzten Jahren kam es zu Entwicklungen, die zu grundlegenden Änderungen der Therapie der transfusionsbedingten Eisenüberladung führen könnten. Neben neuen Medikamenten haben dazu auch neue Untersuchungsverfahren beigetragen, die es u.a. erstmals ermöglichen, den spezifischen Effekt von Chelatbildnern auf die Myokardsiderose zu untersuchen. So haben MRT-Studien Hinweise darauf ergeben, dass DFP in Bezug auf die Myokardsiderose eine im Vergleich zu DFO überlegene Wirksamkeit besitzt. Retrospektive Analysen sowie erste prospektive Studien scheinen dies zu bestätigen.

Parallel wurden Konzepte einer Behandlung mit einer Kombination von DFO und DFP entwickelt. Dabei tragen additive und synergistische Effekte dazu bei, in kurzer Zeit in verschiedenen gefährdeten Organen eine deutliche Eisenelimination zu erreichen.

Die jüngste Entwicklung ist die eines zweiten oralen Chelatbildners, des Deferasirox (DSX). Klinische Studien bei Patienten mit transfusionsbedingter Hämosiderose bei verschiedenen Grunderkrankungen ergaben eine gute Wirksamkeit und Verträglichkeit dieses Chelatbildners. Sollten Langzeitdaten die bisherigen Ergebnisse bestätigen, könnte DSX in zunehmendem Maße eine zentrale Rolle in der Eiseneliminationstherapie einnehmen. Nach vielen Jahren ist damit durch die genannten Entwicklungen erstmals eine Situation entstanden, in der der behandelnde Arzt die für seinen Patienten in einer bestimmten Situation bestgeeignete medikamentöse Eiseneliminationstherapie wählen kann.

Key words

Chelation therapy - hemosiderosis - iron overload - thalassemia - desferrioxamine - deferiprone - deferasirox

Schlüsselwörter

Chelattherapie - Eisenelimination - Hämosiderose - Eisenüberladung - Thalassämie - Desferrioxamine - Deferiprone - Deferasirox

References

• 1 Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.  Acta Haematol. 1990;  84 113-117
• 2 Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2^*) magnetic resonance for the early diagnosis of myocardial iron overload.  Eur Heart J. 2001;  22 2171-2179
• 3 Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.  Lancet. 2002;  360 516-520
• 4 Bannerman RM, Callender ST, Williams DL. Effect of desferrioxamine and DTPA in iron overload.  Br Med J. 1962;  2 1573-1580
• 5 Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.  Br Med J. 1974;  2 16-20
• 6 Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.  Blood. 2006;  107 3733-3737
• 7 Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.  Blood. 2001;  97 792-798
• 8 Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.  N Engl J Med. 1994;  331 567-573
• 9 Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.  Blood. 2006;  107 3455-3462
• 10 Cario H, Stahnke K, Sander S, Kohne E. Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study.  Ann Hematol. 2000;  79 7-12
• 11 Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.  Br J Haematol. 2002;  118 330-336
• 12 Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta -thalassemia.  Blood. 2000;  95 1229-1236
• 13 Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.  Br J Haematol. 2006;  134 438-444
• 14 Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration?.  Blood. 2006;  108 1775-1776
• 15 Fischer R, Piga A, Harmatz P, Nielsen P. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.  Ann N Y Acad Sci. 2005;  1054 350-357
• 16 Gabutti V, Piga A. Results of long-term iron-chelating therapy.  Acta Haematol. 1996;  95 26-36
• 17 Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.  Haematologica/THJ. 2006;  91 1241-1243
• 18 Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.  J Clin Pharmacol. 2003;  43 565-572
• 19 Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.  Haematologica/THJ. 2006;  91 1343-1351
• 20 Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI.  Lancet. 2004;  363 357-362
• 21 Ghugre NR, Enriquez CM, Gonzalez I, Nelson Jr. MD, Coates TD, Wood JC. MRI detects myocardial iron in the human heart.  Magn Reson Med. 2006;  56 681-686
• 22 Grady RW, Berdoukas VA, Rachmilewitz EA, Giardina PJ. Optimizing chelation therapy: combining deferiprone and desferrioxamine.  Blood. 2000;  96 604a
• 23 Greenberg P, Dine G, Ganser A, Verhoef G, DeBusscher L, Quarta G, Zache P, Alimena G, Jeng M, Tchernia G, Gathmann I, Alberti D, Rabault B. Deferasirox (Exjade, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia.  Blood. 2005;  106 2694a
• 24 Hoffbrand AV, Bartlett AN, Veys PA, O'Connor NT, Kontoghiorghes GJ. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.  Lancet. 1989;  2 457
• 25 Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.  Haematologica. 2003;  88 1423-1425
• 26 Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.  Blood Cells Mol Dis. 2006;  36 21-25
• 27 Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.  Br Med J (Clin Res Ed). 1987;  295 1509-1512
• 28 Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.  Lancet. 1987;  1 1294-1295
• 29 Laws HJ, Gobel U, Christaras A, Janssen G. Intensification of chelating-therapy in patients with thalassemia major.  Klin Pädiatr. 2005;  217 120-125
• 30 Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.  Blood Cells Mol Dis. 2002;  28 196-208
• 31 Modell CB, Beck J. Long-term desferrioxamine therapy in thalassemia.  Ann N Y Acad Sci. 1974;  232 201-210
• 32 Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.  Lancet. 2003;  361 1597-1602
• 33 Olivieri NF. The beta-thalassemias.  N Engl J Med. 1999;  341 99-109
• 34 Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia.  Blood. 1997;  89 739-761
• 35 Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.  N Engl J Med. 1998;  339 417-423
• 36 Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia.  N Engl J Med. 1994;  331 574-578
• 37 Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, Leoni G, Muroni PP, Galanello R. Combined therapy with deferiprone and desferrioxamine in thalassemia major.  Haematologica/THJ. 2005;  90 1309-1314
• 38 Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.  Blood. 2006;  107 3738-3744
• 39 Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.  Haematologica. 2003;  88 489-496
• 40 Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.  Haematologica/THJ. 2006;  91 873-880
• 41 Pippard MJ, Letsky EA, Callender ST, Weatherall DJ. Prevention of iron loading in transfusion-dependent thalassaemia.  Lancet. 1978;  1 1178-1181
• 42 Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches.  Semin Hematol. 2005;  42 14-8
• 43 Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG. Continuous subcutaenous administration of deferoxamine in patients with iron overload.  N Engl J Med. 1977;  297 418-423
• 44 Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload.  N Engl J Med. 1976;  294 1421-1423
• 45 Sephton-Smith R. Iron excretion in thalassemia major after administration of chelating agents.  Br Med J. 1962;  2 1577-1582
• 46 St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.  Blood. 2005;  105 855-861
• 47 Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Multi-center validation of the transferability of the magnetic resonance T2^* technique for the quantification of tissue iron.  Haematologica/THJ. 2006;  91 1388-1391
• 48 Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates TD. Investigators tDiSC . A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.  Br J Haematol. 2007;  136 501-508
• 49 Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.  Blood. 2002;  100 1566-1569
• 50 Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R. Cardiac iron determines cardiac T2^*, T2, and T1 in the gerbil model of iron cardiomyopathy.  Circulation. 2005;  112 535-543

Korrespondenzadresse